公开(公告)号：US20230097475A1

公开(公告)日：2023-03-30

申请号：US17795666

申请日：2021-01-29

申请人： Kyoto University ,  TAIHO PHARMACEUTICAL CO., LTD.

发明人： Noriyuki TSUMAKI ,  Yuki IIMORI ,  Akihiro MIURA ,  Hiroshi HIRAI

IPC分类号： A61K31/52 ,  A61P19/08

摘要： A pharmaceutical composition for treating cartilage dysplasia, comprising 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-pyrrolidinyl]-2-propen-1-one or a pharmaceutically acceptable salt thereof, and a treatment method using the pharmaceutical composition.

公开(公告)号：US20190350932A1

公开(公告)日：2019-11-21

申请号：US16448648

申请日：2019-06-21

申请人： TAIHO PHARMACEUTICAL CO., LTD.

发明人： Akihiro MIURA ,  Hiroshi SOOTOME ,  Junya IWASAKI

IPC分类号： A61K31/519 ,  A61P35/00 ,  A61K31/5383

摘要： It is intended to provide a novel method for treating a cancer using an FGFR inhibitor that exhibits a remarkably excellent antitumor effect and has fewer side effects. The present invention provides a combination preparation for the treatment of a malignant tumor comprising a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof, and one or more additional compound(s) having an antitumor effect or pharmaceutically acceptable salt(s) thereof, and a pharmaceutical composition comprising both the active ingredients. The present invention also provides an antitumor effect enhancer, an antitumor agent, a kit for malignant tumor treatment, etc. comprising a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20220241280A1

公开(公告)日：2022-08-04

申请号：US17432158

申请日：2020-02-19

申请人： TAIHO PHARMACEUTICAL CO., LTD.

发明人： Hiroshi HIRAI ,  Akihiro MIURA

IPC分类号： A61K31/519 ,  A61K9/08

摘要： The present invention provides a pharmaceutical composition for treating a patient with an FGFR1 mutant-positive brain tumor, the composition comprising (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one or a pharmaceutically acceptable salt thereof as an active ingredient; and a therapeutic method using the pharmaceutical composition.

公开(公告)号：US20220023300A1

公开(公告)日：2022-01-27

申请号：US17296823

申请日：2019-11-25

申请人： TAIHO PHARMACEUTICAL CO., LTD.

发明人： Hiroshi HIRAI ,  Akihiro MIURA ,  Hiroshi SOOTOME

IPC分类号： A61K31/519 ,  A61K45/06 ,  A61K31/138 ,  A61K31/565 ,  A61P35/00

摘要： Provided is a novel treatment method for cancer tumors to which endocrine therapy is to be applied, using an FGFR inhibitor (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one or a pharmaceutically acceptable salt thereof. Further provided are a pharmaceutical composition comprising the above compound or a pharmaceutically acceptable salt thereof for use in treatment and/or prevention of tumors to which endocrine therapy is to be applied, the pharmaceutical composition being used in combination with endocrine therapy, as well as its related compound, use, method, and combination.

公开(公告)号：US20230165862A1

公开(公告)日：2023-06-01

申请号：US17917765

申请日：2021-04-09

申请人： TAIHO PHARMACEUTICAL CO., LTD.

发明人： Hiroshi HIRAI ,  Kazuaki MATSUOKA ,  Akihiro MIURA

IPC分类号： A61K31/519 ,  A61K31/4184 ,  A61K31/4523 ,  A61P35/04

CPC分类号： A61K31/519 ,  A61K31/4184 ,  A61K31/4523 ,  A61P35/04

摘要： Provided is a novel combination therapy that exhibits excellent antitumor effects, and that uses an FGFR-inhibiting compound and an MEK inhibitor. An antitumor agent contains (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one or a salt thereof as an active ingredient and is administered in combination with an MEK inhibitor.

公开(公告)号：US20200281927A1

公开(公告)日：2020-09-10

申请号：US16082117

申请日：2017-03-03

申请人： TAIHO PHARMACEUTICAL CO., LTD.

发明人： Akihiro MIURA ,  Hiroshi SOOTOME

IPC分类号： A61K31/5025 ,  A61K33/243

摘要： It is intended to provide a novel method for treating a cancer using an FGFR inhibitor that exhibits a remarkably excellent antitumor effect and has fewer side effects. The present invention provides a combination preparation for the treatment of a malignant tumor comprising a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof, and one or more additional compound(s) having an antitumor effect or pharmaceutically acceptable salt(s) thereof, and a pharmaceutical composition comprising both the active ingredients. The present invention also provides an antitumor effect enhancer, an antitumor agent, a kit for malignant tumor treatment, etc. comprising a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof.